312 related articles for article (PubMed ID: 12872354)
1. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A; Gridelli C; De Marinis F; Fabi A; Gamucci T; Cortesi E; Barduagni M; Antimi M; Maione P; Migliorino MR; Giannarelli D; Cognetti F
Cancer; 2003 Jul; 98(2):337-43. PubMed ID: 12872354
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
[TBL] [Abstract][Full Text] [Related]
3. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
Thomas P; Robinet G; Gouva S; Fournel P; Léna H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
Lung Cancer; 2006 Jan; 51(1):105-14. PubMed ID: 16310886
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
Brodowicz T; Krzakowski M; Zwitter M; Tzekova V; Ramlau R; Ghilezan N; Ciuleanu T; Cucevic B; Gyurkovits K; Ulsperger E; Jassem J; Grgic M; Saip P; Szilasi M; Wiltschke C; Wagnerova M; Oskina N; Soldatenkova V; Zielinski C; Wenczl M;
Lung Cancer; 2006 May; 52(2):155-63. PubMed ID: 16569462
[TBL] [Abstract][Full Text] [Related]
6. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
[TBL] [Abstract][Full Text] [Related]
8. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
9. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
Pereira JR; Fein L; Del Giglio A; Blajman CR; Richardet E; Schwartsmann G; Orlando M; Hall BJ; West TM; van Kooten M
Lung Cancer; 2007 Oct; 58(1):80-7. PubMed ID: 17588704
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
Sandler AB; Nemunaitis J; Denham C; von Pawel J; Cormier Y; Gatzemeier U; Mattson K; Manegold C; Palmer MC; Gregor A; Nguyen B; Niyikiza C; Einhorn LH
J Clin Oncol; 2000 Jan; 18(1):122-30. PubMed ID: 10623702
[TBL] [Abstract][Full Text] [Related]
13. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
Rosell R; Tonato M; Sandler A
Semin Oncol; 1998 Aug; 25(4 Suppl 9):27-34. PubMed ID: 9728582
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
15. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
[TBL] [Abstract][Full Text] [Related]
16. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
Smit EF; van Meerbeeck JP; Lianes P; Debruyne C; Legrand C; Schramel F; Smit H; Gaafar R; Biesma B; Manegold C; Neymark N; Giaccone G;
J Clin Oncol; 2003 Nov; 21(21):3909-17. PubMed ID: 14581415
[TBL] [Abstract][Full Text] [Related]
17. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
Zwitter M; Kovac V; Rajer M; Vrankar M; Smrdel U
Anticancer Drugs; 2010 Jul; 21(6):662-8. PubMed ID: 20453635
[TBL] [Abstract][Full Text] [Related]
18. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.
Rinaldi M; Crinò L; Scagliotti GV; Mosconi AM; De Marinis F; Gridelli C; Selvaggi G; Della Giulia M; Darwish S; Porrozzi S; Novello S; Cipri A; Bartolucci R; Calandri C; Tonato M
Ann Oncol; 2000 Oct; 11(10):1295-300. PubMed ID: 11106119
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]